Considerations when analyzing the methylation status of PTEN tumor suppressor gene

被引:101
作者
Zysman, MA
Chapman, WB
Bapat, B
机构
[1] Mt Sinai Hosp, Samuel Lunenfeld Res Inst, Toronto, ON M5G 1X5, Canada
[2] Univ Toronto, Fac Med, Dept Lab Med & Pathobiol, Toronto, ON, Canada
[3] Univ Hlth Network, Toronto, ON, Canada
关键词
D O I
10.1016/S0002-9440(10)64902-4
中图分类号
R36 [病理学];
学科分类号
100104 ;
摘要
Epigenetic mechanisms of gene silencing, including promoter hypermethylation of tumor suppressor genes, have been shown to contribute to tumorigenesis. PTEN is an important tumor suppressor implicated in the pathogenesis of a number of familial and sporadic cancers. Germline mutations of PTEN predispose to dominantly inherited hamartomatous disorders Cowden syndrome and Bannayan-Zonana syndrome. Somatic PTEN mutations commonly occur in endometrial, breast, prostate, and thyroid tumors. Several investigators have speculated on PTEN promoter hypermethylation as a possible mechanism of PTEN inactivation but data supporting such observations is not forthcoming. The genomic sequence of PTEN is 98% identical to a highly conserved processed PTEN pseudogene (psiPTEN) and this sequence identity extends 841 base pairs into the promoter region. This high degree of homology has made analysis of the methylation status of the PTEN promoter quite challenging. We have investigated the methylation profiles of the promoter region of PTEN in endometrial, breast, and colon cancer cell fines, as well as in a panel of primary endometrial tumors using a combination of methylation-specific polymerase chain reaction, methylation-sensitive restriction analysis, and bisulfite sequencing. our results show that the pseudogene, and not PTEN, is predominantly methylated in cell lines and tumors. Without careful consideration of the critical nucleotide differences between the two sequences, results obtained from PTEN analysis may not necessarily represent the methylation status of PTEN.
引用
收藏
页码:795 / 800
页数:6
相关论文
共 24 条
[1]   Gatekeeper for endometrium: the PTEN tumor suppressor gene [J].
Ali, IU .
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2000, 92 (11) :861-863
[2]  
Cairns P, 1997, CANCER RES, V57, P4997
[3]  
Costello JF, 1996, CANCER RES, V56, P2405
[4]   A highly conserved processed PTEN pseudogene is located on chromosome band 9p21 [J].
Dahia, PLM ;
FitzGerald, MG ;
Zhang, X ;
Marsh, DJ ;
Zheng, ZM ;
Pietsch, T ;
von Deimling, A ;
Haluska, FG ;
Haber, DA ;
Eng, C .
ONCOGENE, 1998, 16 (18) :2403-2406
[5]  
Dahia PLM, 1997, CANCER RES, V57, P4710
[6]  
Esteller M, 2000, CANCER RES, V60, P4366
[7]   hMLH1 promoter hypermethylation is an early event in human endometrial tumorigenesis [J].
Esteller, M ;
Catasus, L ;
Matias-Guiu, X ;
Mutter, GL ;
Prat, J ;
Baylin, SB ;
Herman, JG .
AMERICAN JOURNAL OF PATHOLOGY, 1999, 155 (05) :1767-1772
[8]   Methylation-specific PCR: A novel PCR assay for methylation status of CpG islands [J].
Herman, JG ;
Graff, JR ;
Myohanen, S ;
Nelkin, BD ;
Baylin, SB .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1996, 93 (18) :9821-9826
[9]   Frequent loss of PTEN expression is linked to elevated phosphorylated Akt levels, but not associated with p27 and cyclin D1 expression, in primary epithelial ovarian carcinomas [J].
Kurose, K ;
Zhou, XP ;
Araki, T ;
Cannistra, SA ;
Maher, ER ;
Eng, C .
AMERICAN JOURNAL OF PATHOLOGY, 2001, 158 (06) :2097-2106
[10]  
Levine RL, 1998, CANCER RES, V58, P3254